INSIGHTS+ Archives - Page 7 of 37

The US FDA New Drug Approvals in September 2024

Shots: PharmaShots has compiled a list of US FDA-approved drugs in the month of September 2024 The US FDA has approved a total of 7 new drugs including 4 new molecular entities and 3 biologics leading to the treatment of patients and advances in the healthcare industry The major highlighted drugs were Roche’s Tecentriq Hybreza & Ocrevus Zunovo for…

October 22, 2024

Know Your Investor: Samsara Biocapital (October’24 Edition)

Shots: A California-based venture capital fund, Samsara Biocapital partners with medical companies and scientists to infuse cutting-edge innovations in medicines In 2023, Samsara participated in five funding rounds and invested around $2.3B to add 19 companies to its portfolio For a curated report on a specific investor or venture capital, reach out to us at connect@pharmashots.com …

October 17, 2024

Disease of the Month – Psoriatic arthritis

Shots: Psoriatic arthritis is a chronic inflammatory condition characterized by joint pain, stiffness and swelling In this reprise of our Disease of the Month report, we present an enlightening description of Psoriatic arthritis with a thorough study of epidemiology, market size, disease management, potential medicines, patient advocacy groups, and the key players involved For a…

October 16, 2024

Key Biosimilars Events of September 2024

Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency   Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients   The major highlights were the US FDA’s approval of Samsung Bioepis and…

October 3, 2024

PharmaShots’ Key Highlights of Third Quarter 2024

Shots: The third quarter of 2024 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The highlight of the quarter was Eli Lilly's acquisition of Morphic Holdings for ~$3.2B This quarter also showcased multiple clinical trial results including Roche's P-I Study Data of CT-996 to treat Obesity Our…

October 1, 2024

New Drug Designations – August 2024

Shots: PharmaShots' designation report provides a concise overview of several drugs and their designations by the FDA, NMPA and EMA. August month’s report includes designations allotted to 10 small molecules, 9 biologics, 7 cell & gene therapies, 1 vaccine, 2 radiopharmaceutical, 1 peptide, 1 antineoplastic and 2 devices In August 2024, Invenra’s INV724 received the…

September 25, 2024

Insights+: EMA Marketing Authorization of New Drugs in August 2024

Shots: The EC has approved to 5 Biologics and 3 New Chemical Entities in August 2024, leading to treatments for patients and advances in the healthcare industry The major highlighted drugs were Johnson & Johnson’s Balversa to treat Metastatic Urothelial Carcinoma (mUC) and Takeda’s Adzynma for Congenital Thrombotic Thrombocytopenic Purpura (cTTP) PharmaShots has compiled a list…

September 24, 2024

Disease of the Month – Systemic Lupus Erythematosus

Shots: Systemic lupus erythematosus (SLE) is an autoimmune disorder where the body's immune system targets and damages healthy tissues In this reprise of our Disease of the Month report, we present an enlightening description of SLE with a thorough study of epidemiology, market size, disease management, potential medicines, patient advocacy groups, and the key players involved For a…

September 18, 2024

Insights+: The US FDA New Drug Approvals in August 2024

Shots: PharmaShots has compiled a list of US FDA-approved drugs in the month of August 2024 The US FDA has approved a total of 7 new drugs including 4 new molecular entities and 3 biologics leading to the treatments for patients and advances in the healthcare industry The major highlighted drug was Johnson & Johnson’s Rybrevant plus Lazcluze…

September 10, 2024

Know Your Investor: BVF Partners L.P. (September’24 Edition)

Shots: An equity hedge fund manager company, BVF Partners invests in small cap and early-stage biotechnology companies In 2023, BVF participated in five investment rounds and added 20 companies to its portfolio For a curated report on a specific investor or venture capital, reach out to us at connect@pharmashots.com Established in 1993 in San Francisco, California,…

September 5, 2024

INSIGHTS+